Korean Circ J.  2018 Dec;48(12):1145-1147. 10.4070/kcj.2018.0250.

New Therapeutic Target for Pulmonary Arterial Hypertension

• Yoon KL

• KMID: 2424564
• DOI: http://doi.org/10.4070/kcj.2018.0250

Abstract

No abstract available.

MeSH Terms

Hypertension*

Reference

1. Stenmark KR, Rabinovitch M. Emerging therapies for the treatment of pulmonary hypertension. Pediatr Crit Care Med. 2010; 11:S85–S90.

2. Marcu R, Kotha S, Zhi Z, et al. The mitochondrial permeability transition pore regulates endothelial bioenergetics and angiogenesis. Circ Res. 2015; 116:1336–1345.

3. Broughton KM, Wang BJ, Firouzi F, et al. Mechanisms of cardiac repair and regeneration. Circ Res. 2018; 122:1151–1163.

4. Yu L, Tu Y, Jia X, et al. Resveratrol protects against pulmonary arterial hypertension in rats via activation of silent Information regulator 1. Cell Physiol Biochem. 2017; 42:55–67.

5. Li Z, Chen S, Ma K, et al. CsA attenuates compression-induced nucleus pulposus mesenchymal stem cells apoptosis via alleviating mitochondrial dysfunction and oxidative stress. Life Sci. 2018; 205:26–37.

6. Lee DS, Jung YW. Protective effect of right ventricular mitochondrial damage by cyclosporine A in monocrotaline-induced pulmonary hypertension. Korean Circ J. 2018; 48:1135–1144.

7. Kim KC, Lee JC, Lee H, Cho MS, Choi SJ, Hong YM. Changes in caspase-3, B cell leukemia/lymphoma-2, interleukin-6, tumor necrosis factor-α and vascular endothelial growth factor gene expression after human umbilical cord blood derived mesenchymal stem cells transfusion in pulmonary hypertension rat models. Korean Circ J. 2016; 46:79–92.

8. McGee M, Whitehead N, Martin J, Collins N. Drug-associated pulmonary arterial hypertension. Clin Toxicol (Phila). 2018; 6:1–9.

9. Burks M, Stickel S, Galiè N. Pulmonary arterial hypertension: combination therapy in practice. Am J Cardiovasc Drugs. 2018; 18:249–257.